This segment focuses on the research, development, and commercialization of treatments for severe allergic reactions, specifically anaphylaxis. The core technology is neffy, a needle-free, low-dose epinephrine nasal spray. Research and development activities include clinical trials to demonstrate efficacy and safety, as well as formulation improvements and manufacturing process optimization. The therapeutic area is Type I allergic reactions, including anaphylaxis. The patient impact is significant, offering a convenient and potentially life-saving alternative to epinephrine auto-injectors. Market positioning centers on providing a user-friendly and effective treatment option. Competitive advantages include the needle-free delivery system and the potential for improved patient compliance. Future opportunities include expanding the product's availability and exploring additional indications. Regulatory aspects involve obtaining and maintaining FDA approval and compliance with manufacturing standards. Partnerships with global allergy leaders like ALK and CSL Seqirus are key to commercialization in various regions.